Cargando…

The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer

In clinical decision‐making, to decide the indication for adjuvant chemotherapy for estrogen receptor‐positive (ER+), human epidermal growth factor receptor‐2‐negative (HER2−), and node‐negative (n0) breast cancer patients, the accurate estimation of recurrence risk is essential. Unfortunately, conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Naoi, Yasuto, Tsunashima, Ryo, Shimazu, Kenzo, Noguchi, Shinzaburo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019222/
https://www.ncbi.nlm.nih.gov/pubmed/33544932
http://dx.doi.org/10.1111/cas.14838
_version_ 1783674335132647424
author Naoi, Yasuto
Tsunashima, Ryo
Shimazu, Kenzo
Noguchi, Shinzaburo
author_facet Naoi, Yasuto
Tsunashima, Ryo
Shimazu, Kenzo
Noguchi, Shinzaburo
author_sort Naoi, Yasuto
collection PubMed
description In clinical decision‐making, to decide the indication for adjuvant chemotherapy for estrogen receptor‐positive (ER+), human epidermal growth factor receptor‐2‐negative (HER2−), and node‐negative (n0) breast cancer patients, the accurate estimation of recurrence risk is essential. Unfortunately, conventional prognostic factors, such as tumor size, histological grade and ER, progesterone receptor (PR), and HER2 status as well as Ki67 index, are not sufficiently accurate for such estimation. Therefore, several multigene assays (MGAs) based on the mRNA expression analysis of multiple genes in tumor tissue have been developed to better predict patient prognosis. These assays include Oncotype DX, MammaPrint, PAM50, GGI, EndoPredict, and BCI. We developed Curebest™ 95‐Gene Classifier Breast (95GC) classifier, which is unique in that mRNA expression data of all 20 000 human genes are secondarily obtainable, as the 95GC assay is performed using Affymetrix microarray. This can capture mRNA expression of not only 95 genes but also every gene at once, and such gene expression data can be utilized by the other MGAs that we have developed, such as the 155GC, which is used for the prognostic prediction of ER+/HER2− breast cancer patients treated with neoadjuvant chemotherapy. We also developed the 42GC for predicting late recurrence in ER+/HER2− breast cancer patients. In this mini‐review, our recent attempt at the development of various MGAs, which is expected to facilitate the implementation of precision medicine in ER+/HER2− breast cancer patients, is presented with a special emphasis on 95GC.
format Online
Article
Text
id pubmed-8019222
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80192222021-04-08 The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer Naoi, Yasuto Tsunashima, Ryo Shimazu, Kenzo Noguchi, Shinzaburo Cancer Sci Review Articles In clinical decision‐making, to decide the indication for adjuvant chemotherapy for estrogen receptor‐positive (ER+), human epidermal growth factor receptor‐2‐negative (HER2−), and node‐negative (n0) breast cancer patients, the accurate estimation of recurrence risk is essential. Unfortunately, conventional prognostic factors, such as tumor size, histological grade and ER, progesterone receptor (PR), and HER2 status as well as Ki67 index, are not sufficiently accurate for such estimation. Therefore, several multigene assays (MGAs) based on the mRNA expression analysis of multiple genes in tumor tissue have been developed to better predict patient prognosis. These assays include Oncotype DX, MammaPrint, PAM50, GGI, EndoPredict, and BCI. We developed Curebest™ 95‐Gene Classifier Breast (95GC) classifier, which is unique in that mRNA expression data of all 20 000 human genes are secondarily obtainable, as the 95GC assay is performed using Affymetrix microarray. This can capture mRNA expression of not only 95 genes but also every gene at once, and such gene expression data can be utilized by the other MGAs that we have developed, such as the 155GC, which is used for the prognostic prediction of ER+/HER2− breast cancer patients treated with neoadjuvant chemotherapy. We also developed the 42GC for predicting late recurrence in ER+/HER2− breast cancer patients. In this mini‐review, our recent attempt at the development of various MGAs, which is expected to facilitate the implementation of precision medicine in ER+/HER2− breast cancer patients, is presented with a special emphasis on 95GC. John Wiley and Sons Inc. 2021-02-26 2021-04 /pmc/articles/PMC8019222/ /pubmed/33544932 http://dx.doi.org/10.1111/cas.14838 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Naoi, Yasuto
Tsunashima, Ryo
Shimazu, Kenzo
Noguchi, Shinzaburo
The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
title The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
title_full The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
title_fullStr The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
title_full_unstemmed The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
title_short The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
title_sort multigene classifiers 95gc/42gc/155gc for precision medicine in er‐positive her2‐negative early breast cancer
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019222/
https://www.ncbi.nlm.nih.gov/pubmed/33544932
http://dx.doi.org/10.1111/cas.14838
work_keys_str_mv AT naoiyasuto themultigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer
AT tsunashimaryo themultigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer
AT shimazukenzo themultigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer
AT noguchishinzaburo themultigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer
AT naoiyasuto multigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer
AT tsunashimaryo multigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer
AT shimazukenzo multigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer
AT noguchishinzaburo multigeneclassifiers95gc42gc155gcforprecisionmedicineinerpositiveher2negativeearlybreastcancer